Let me rephrase. No trial results they'll pay attention too because CD10 didn't hit stat sig in primary endpoint. Regeneron has good interim results from 275 patients. If things turn dire for Trump maybe, just maybe they'll ask for an early look at the data while still keeping it segregated from the company.

With the tweet storms fired off Trump's team, the FDA and the CDC should know about leronlimab by now. I wonder if doctors at Bethesda Naval Hospital or wherever he's been shipped to have faced the tidal wave of tweets yet?